Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) Clinical Trial

Official title:
A Phase 1b/2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination With Bempegaldesleukin(NKTR-214) With or Without Talazoparib or Enzalutamide in Participants With Locally Advanced or Metastatic Solid Tumors

Status Terminated

Clinical Trial Summary

Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or enzalutamide in metastatic castration resistant prostate cancer (mCRPC).

Clinical Trial Description

Phase 1b/ Phase 2 Design Phase 1b will be the sequential dose-finding study. Once the Phase 1b component is completed, Phase 2 will be initiated to further evaluate the safety and anti-tumor activity across combinations of therapy. Combination A will enroll participants with SCCHN. Combination B and C will enroll participants with mCRPC ;

Study Design

Related Conditions & MeSH terms

Metastatic Castration Resistant Prostate Cancer (mCRPC)
Squamous Cell Carcinoma of Head and Neck
Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Clinical Trial Details

NCT number	NCT04052204
Study type	Interventional
Source	Pfizer
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	December 30, 2019
Completion date	September 29, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01204099` - Study of PX-866 and Docetaxel in Solid Tumors	Phase 1/Phase 2
Completed	`NCT02499120` - Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer	Phase 2
Active, not recruiting	`NCT04989387` - Study of INCA 0186 in Subjects With Advanced Solid Tumors	Phase 1
Completed	`NCT00392665` - Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck	Phase 2
Active, not recruiting	`NCT05057247` - Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC	Phase 2
Completed	`NCT02001623` - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors	Phase 1/Phase 2
Terminated	`NCT01285635` - A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck	Phase 2
Completed	`NCT03538028` - A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies	Phase 1
Completed	`NCT02335918` - A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors	Phase 1/Phase 2
Completed	`NCT03405142` - Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer	Phase 2